Truist Financial Begins Coverage on Voyager Therapeutics (NA

Truist Financial began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR – Get Rating) in a research note published on Wednesday morning, The Fly reports. The firm issued a buy rating and a $18.00 target price on the stock. VYGR has been the subject of several other research reports. StockNews.com cut shares of Voyager Therapeutics from […]

Related Keywords

Robertw Hesslein , , Voyager Therapeutics Company Profile , Millennium Management , Voyager Therapeutics Inc , Neurocrine Biosciences Inc , Armistice Capital , Securities Exchange Commission , Marshall Wace , Pricet Rowe Associates Inc , Tau Program , Truist Financial , Voyager Therapeutics , Get Rating , Exchange Commission , Guang Ping Gao , Voyager Therapeutics Daily , Nasdaq Vygr , Vygr , Medical , Initiated Coverage , Truist Financial Co ,